| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2003;34:2399.)
© 2003 American Heart Association, Inc.
Original Contributions |
From Intensive Care Medicine (Y.K., H. Hinohara, K. Kunimoto) and the Department of Anesthesiology and Reanimatology(S.S., M.I., H. Hiraoka, F. Kawahara, F.G.), Gunma University School of Medicine, Gunma, Japan.
Correspondence to Yuji Kadoi, Intensive Care Medicine, Gunma University School of Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma 371-8511, Japan. E-mail kadoi{at}med.gunma-u.ac.jp
| Abstract |
|---|
|
|
|---|
Methods Thirty diabetic patients consecutively scheduled for elective major surgery were studied. After induction of anesthesia, a 2.5-MHz pulsed transcranial Doppler probe was attached to the patients head at the right temporal window, and mean blood flow velocity of the middle cerebral artery (Vmca) was measured continuously. After the baseline Vmca, arterial blood gases, and cardiovascular hemodynamic values were measured, end-tidal CO2 was increased by reducing ventilatory frequency by 2 to 5 breaths per minute. Measurements were repeated when end-tidal CO2 increased and remained stable for 5 to 10 minutes.
Results Significant differences were observed in absolute and relative CO2 reactivity between the diabetes and control groups (absolute CO2 reactivity: control, 2.8±0.7; diabetes mellitus, 2.1±1.3; P<0.01; relative CO2 reactivity: control, 6.3±1.4; diabetes mellitus, 4.5±2.7; P<0.01, Mann-Whitney U test). Significant differences were also found between diabetic patients with retinopathy and those without retinopathy in absolute (P=0.002) and relative (P=0.002) CO2 reactivity, glycosylated hemoglobin (P=0.0034), and fasting blood sugar (P=0.01) (Scheffés test, Mann-Whitney U test). There was an inverse correlation between absolute CO2 reactivity and glycosylated hemoglobin (r=0.69, P<0.001).
Conclusions Insulin-dependent diabetic patients have an impaired vasodilatory response to hypercapnia compared with that of the control group, and the present findings suggest that their degree of impairment is related to the severity of diabetes mellitus.
Key Words: carbon dioxide diabetes mellitus vasodilation
| Introduction |
|---|
|
|
|---|
In this study, we examined the effects of diabetes mellitus and its severity on the cerebral vasodilatory response to hypercapnia.
| Patients and Methods |
|---|
|
|
|---|
Patients were defined as having diabetes mellitus if their medical records showed a diagnosis of type 2 diabetes and current medical treatment with antidiabetic therapy such as diet, oral, or insulin therapy. Duration of disease was defined as the duration from the start of medical treatment. Patients with a history of cerebrovascular disease, psychiatric illness, active liver disease (glutamine oxaloacetate transaminase or glutamine pyruvate transaminase >50 U/dL) were excluded. All patients were examined preoperatively for the presence of carotid artery stenosis by ultrasonography and MRI. The presence of carotid artery stenosis was defined as luminal narrowing >50%.9 Three diabetic patients had moderate or severe carotid artery stenosis and were therefore excluded. In addition, all patients were examined for the presence of silent lacunar infarction by preoperative brain CT and MR tomography. Two diabetic patients had silent lacunar infarction and were excluded. A total of 30 diabetic patients met the entry criteria.
All enrolled patients had undergone ophthalmologic examination for detection of diabetic retinopathy. According to the modification of the Diabetic Retinopathy Study and the Early Treatment Diabetic Retinopathy grading scale, the severity of the worst affected eye was used, and patients with retinopathy were further divided into 3 categories: those with mild to moderate nonproliferative diabetic retinopathy (NPDR); those with a severe stage of NPDR; and those with proliferative diabetic retinopathy (PDR).10
Because glycosylated hemoglobin (HbA1c) (normal value, 4.5% to 5.8%) is an indicator of well-or poorly controlled diabetes mellitus, all diabetic patients were examined for preoperative HbA1c level.
As a control, 30 age-matched nondiabetic patients consecutively scheduled for elective major surgery were studied.
Anesthesia was induced by 0.1 mg/kg midazolam, 5 µg/kg fentanyl, and 0.2 mg/kg vecuronium, and the trachea was intubated. After anesthesia induction, 3 to 5 mg · kg-1 · h-1 propofol was infused with a syringe pump and was continued until the patients arrived at the intensive care unit. Muscular relaxation was achieved by intermittent administration of vecuronium. No volatile anesthetic was administrated. All patients were ventilated with oxygen 50% and N2 50%. End-tidal carbon dioxide (PetCO2) was monitored (UltimaR, Datex). PaO2 was maintained at 150 to 300 mm Hg during the study. Tympanic membrane temperature was continuously monitored by Mon-a-ThermR (Mallinckrodt Co).
The study was performed after the induction of anesthesia, before the start of surgery, and during the stable hemodynamic period (
20 to 30 minutes after the induction of anesthesia). A 2.5-MHz pulsed transcranial Doppler (TCD) probe was attached to the patients head at the right temporal window, and mean blood flow velocity of the middle cerebral artery (Vmca) was measured continuously (Hewlett-Packard SONOS 5500R, 2.5-MHz transducer). After the signals were identified at a depth of 45 to 60 mm, the probe was fixed with a probe folder so as to not change the insonating angle. The Vmca value at end expiration was recorded.
After baseline Vmca, arterial blood gases, and cardiovascular hemodynamic values were measured, PetCO2 was increased by reducing the ventilatory frequency by 2 to 5 breaths per minute. This resulted in an increase in PaCO of
6 to 9 mm Hg within several minutes. The measurements were repeated when PetCO2 increased and remained stable for 5 to 10 minutes.
The cerebral vasodilatory response to hypercapnia in each patient was calculated as both the absolute change in Vmca (cm · s-1 · mm Hg-1) and the percentage change in Vmca (percentage of baseline Vmca/mm Hg) per millimeter of mercury change in PaCO using the following formulas4: absolute CO2 reactivity=
Vmca/
PaCO2; relative CO2 reactivity=(
Vmca/
PaCO2/baseline Vmca)x100, where
Vmca is the difference between flow velocity after PaCO2 elevation and baseline flow velocity, and
PaCO2 is the difference between final PaCO2 and baseline PaCO2.
Statistical Analysis
All data were expressed as mean±SD. An unpaired t test and Mann-Whitney U test or Scheffés test were used for analysis. Statistical significance was set at P<0.05.
Association of absolute CO2 reactivity in diabetic patients was evaluated with a stepwise linear regression model, taking into consideration fasting blood sugar, duration of disease, diabetic therapy, HbA1c, and retinopathy.
After the study was completed, we evaluated sample size, which was calculated from the hypothesis that absolute CO2 reactivity in insulin-dependent diabetic patients would be decreased by 1.0 cm · s-1 · mm Hg-1 compared with that in control patients. The sample size provides 90% power to detect a 10% difference between groups with a 5% probability of an a-type error. In addition, sample size calculation was based on the hypothesis that absolute CO2 reactivity in diabetic patients with retinopathy would be decreased by 1.0 cm · s-1 · mm Hg-1 compared with that in diabetic patients without retinopathy. The sample size provides 80% power to detect a 20% difference between groups with a 5% probability of an a-type error.
All calculations were performed on a Macintosh computer with SPSS (SPSS, Inc) and Stat View 5.0 (Abacus Concepts, Inc) software packages.
| Results |
|---|
|
|
|---|
|
|
Because of the heterogeneous population of diabetes mellitus in this study, we subdivided the diabetes group into 3 groups: diet, glibenclamide, and insulin groups (Table 3). Significant differences were found in the absolute (P=0.048) and relative (P=0.024) CO2 reactivity between the insulin group and the other 2 diabetic groups (Scheffés test). In addition, we subdivided the diabetes group into 2 groups: patients with retinopathy and patients without retinopathy (Table 3). Significant differences were observed in the absolute (P=0.002) and relative (P=0.002) CO2 reactivity, HbA1c (P=0.0034), and fasting blood sugar (P=0.01) between groups (Scheffés test, Mann-Whitney U test).
|
In addition, we subdivided the diabetes patients with retinopathy into 3 groups: patients with mild to moderate NPDR, patients with severe NPDR, and patients with PDR (Table 3). However, there were no significant differences in the absolute (P=0.63) and relative (P=0.62) CO2 reactivity between groups (Scheffés test).
Stepwise linear regression showed that HbA1c was the only inverse factor related to absolute CO2 reactivity (Y=6.832 to 0.783X, r=0.69, P<0.001).
There were no significant differences in mean arterial pressure, heart rate, PaO2, and tympanic membrane temperature both at pretreatment and posttreatment between the groups.
| Discussion |
|---|
|
|
|---|
Before interpreting our results, we should discuss the validity of TCD measurement. Dahl et al11 reported that changes in blood flow velocity measured by TCD correlated well with changes in blood flow measured by single-photon emission CT. Sugimori et al12 examined blood flow velocity with TCD in the middle cerebral artery and cerebrovascular vasodilator responses to CO2 in 22 patients with or without carotid artery occlusive disease and minor stroke. They concluded that TCD is a reliable method to evaluate decreases in the cerebral circulation in patients with hypertension or diabetes mellitus.
There have been controversial results regarding the effects of diabetes mellitus on cerebral circulation.17 Croughwell et al1 examined cerebral metabolic autoregulation during the cardiopulmonary bypass period using the 133Xe-clearance method and reported that the CBF of their diabetic group remained constant despite an increase in temperature from 27°C to 37°C, in contrast to an 83% increase in CBF in the control group. They concluded that diabetic patients lose cerebral autoregulation during cardiopulmonary bypass and compensate for an imbalance in adequate oxygen delivery by increasing oxygen extraction. In a previous study,8 we found a significant difference in the mean slopes of jugular venous oxygen saturation versus CPP for increasing CPP between insulin-dependent diabetic patients and diabetic patients on diet therapy and glibenclamide therapy.
In regard to cerebrovascular CO2 reactivity in diabetic patients, Griffith et al13 reported that of 22 diabetic patients, 14 responded normally and 8 failed to show a significant increase in CBF after hypercapnia when the 133Xe-clearance method was used. Dandona et al2,3 reported that there was a significant variation in CBF after administration of 5% CO2 in insulin-dependent diabetics compared with normal subjects using the 133Xe-inhalation method, concluding that diabetics had diminished cerebrovascular reserve and were unable to compensate when necessary with an increased CBF. Rodriguez et al14 reported that compared with control subjects, the percentage of global CBF increment measured by the 133Xe-inhalation method after acetazolamide administration was significantly impaired in 4 insulin-dependent diabetic patients and was a borderline response in 2 insulin-dependent diabetic patients. In contrast, Kawata et al4 examined the effects of diabetes mellitus on CO2 reactivity using TCD and found that the relative values of CO2 reactivity in diabetic patients were equivalent to those of control subjects during isoflurane anesthesia. Sieber et al5,6 reported that 4 months of hyperglycemia in an animal model increased both CBF and the cerebral metabolic rate for oxygen. They speculated that the effects of diabetes mellitus on the cerebral vasculature were complicated by a host of factors, including diabetic microangiopathy, atherosclerosis, hypertension, renal disease, and chronic hyperglycemia, and concluded that it was likely that many of the reported abnormalities in CBF physiology were the result of diabetic vascular disease rather than hyperglycemia.
In the present study, diabetic patients with retinopathy had abnormal cerebrovascular CO2 reactivity compared with diabetic patients without retinopathy and the control groups. It is not clear why the presence of retinopathy was associated with abnormal cerebrovascular CO2 reactivity. However, it has been reported that retinal circulation might represent the cerebrovascular circulation10,15 because the retina develops from the forebrain.16 Abnormal cerebral microangiopathy in diabetic patients would be represented by diabetic retinopathy. In addition, Stratton et al17 reported that in patients with type 2 diabetes, the risk of diabetic complications such as macrovascular and microvascular disease was strongly associated with previous hyperglycemia. This implies that the primary cause of microvascular disease is chronic hyperglycemia itself. The fact that HbA1c was related to impaired CO2 reactivity in our study suggests that impaired CO2 reactivity was responsible for microvascular disease in the brain, which was induced by hyperglycemia.
This present study is the first to show that HbA1c and retinopathy are related to an impaired vasodilatory response to CO2. This finding is inconsistent with those of Griffith et al13 and Rodriguez et al.14 Rodriguez et al14 reported that duration of diabetes, serum glucose concentration, and HbA1c did not correlate with the percentage of postacetazolamide global CBF changes. This discrepancy might be due in part to differences in demographic data. The mean age of the subject of Rodriguez et al16 was 30 years; that of our subjects was 64 years. Age is a factor associated with the cerebral vasodilatory response to hypercapnia.18 Hartl et al19 reported that absolute and relative mean CO2 reactivities in elderly subjects were markedly lower than those in young subjects. In contrast, Yamamoto et al18 examined the effect of aging on cerebral vasodilator responses to hypercapnia and found that mean CBF in the elderly was
10% to 20% less than in young volunteers and that vasodilatory response to hypercapnia in elderly patients without risk factors was similar to that in young volunteers. Another possible mechanism might be prolonged hyperglycemia. Stratton et al17 reported that in patients with type 2 diabetes, the risk of diabetic macrovascular and microvascular complications was strongly associated with previous hyperglycemia. Klein et al15 reported that HbA1c predicted the incidence and progression of diabetic retinopathy. In addition, Pallas and Larson20 noted that hyperglycemia leads to impaired vascular function through endothelial cell function. The pathway that appears most affected by the diabetic state is that of nitric oxide. Loss of this pathway is accompanied by loss of response to PaCO and lack of autoregulation related to flow-pressure relationships.
In this study, we examined the response to PaCO using hypoventilation to increase middle cerebral artery velocity rather than using hyperventilation to decrease middle cerebral artery velocity. Cenic et al21 reported that cerebrovascular CO2 reactivity was maintained during hypercapnia but was markedly diminished during hypocapnia under propofol anesthesia. We examined the cerebrovascular vasodilatory response to CO2 in diabetic patients using hypoventilation to rule out the possibility that hyperventilation would have some effect on the cerebral vasodilatory response to hypercapnia.
Study Limitations
Some factors such as blood pressure, cardiac output, temperature, cerebral metabolism, and anesthetic agents are likely to influence CBF. In this study, no changes were observed in arterial blood pressure, tympanic membrane temperature, or anesthetic depth at pretreatment and posttreatment. Thus, we conclude that changes in CBF velocity were attributable to changes in PaCO.
We examined the cerebral vasodilatory response to hypercapnia under propofol anesthesia. Propofol has been widely used for neurosurgical anesthesia and as a sedative agent in intensive care units.22 It is important for anesthesiologists and intensivists to know whether cerebrovascular CO2 reactivity in diabetic patients is intact. However, there are no data describing this under propofol anesthesia. Some reports have described the effects of propofol on cerebrovascular CO2 reactivity.10,23,24 Matta et al23 examined cerebral CO2 reactivity using TCD during propofol-induced electrical silence of the electroencephalogram in 10 patients undergoing anesthesia for nonneurosurgical procedures (mean age, 37 years) and found that cerebral CO2 reactivity remained intact during propofol anesthesia. Fox et al24 reported in 7 patients undergoing elective gynecologic or orthopedic surgery (mean age, 40.5±7 years) that the slope of the CBF-CO2 response measured by the 133Xe-inhalation method was similar to that found in awake individuals and during propofol-nitrous oxide anesthesia. Myburgh et al22 reported in sheep (n=6) that the mean slopes of the CO2 reactivity curves in the sagittal sinus measured by a Doppler probe did not differ between awake conditions and propofol anesthesia. However, the possibility that propofol exerts some effect only on cerebrovascular CO2 reactivity in diabetic patients cannot be ruled out.
The number of patients with nephropathy (n=1) or neuropathy (n=1) was too small to consider them indicators of the severity of diabetes. Further study is necessary to clarify the relationship between neuropathy and nephropathy as indicators of severity of diabetes.
Stepwise linear regression showed that only HbA1c was a factor related to absolute CO2 reactivity. This finding might point to HbA1c is an indicator of the severity of diabetic microangiopathy in brain.
In conclusion, insulin-dependent diabetic patients showed an impaired vasodilatory response to hypercapnia compared with that of the control group, and our data suggest that this impaired response was related to severity of diabetes mellitus.
| Acknowledgments |
|---|
Received December 11, 2002; revision received March 31, 2003; accepted May 9, 2003.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y. Kadoi, S. Saito, C. Kawauchi, H. Hinohara, and F. Kunimoto Comparative effects of propofol vs dexmedetomidine on cerebrovascular carbon dioxide reactivity in patients with septic shock Br. J. Anaesth., February 1, 2008; 100(2): 224 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Last, D. C. Alsop, A. M. Abduljalil, R. P. Marquis, C. de Bazelaire, K. Hu, J. Cavallerano, and V. Novak Global and Regional Effects of Type 2 Diabetes on Brain Tissue Volumes and Cerebral Vasoreactivity Diabetes Care, May 1, 2007; 30(5): 1193 - 1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Novak, D. Last, D. C. Alsop, A. M. Abduljalil, K. Hu, L. Lepicovsky, J. Cavallerano, and L. A. Lipsitz Cerebral Blood Flow Velocity and Periventricular White Matter Hyperintensities in Type 2 Diabetes Diabetes Care, July 1, 2006; 29(7): 1529 - 1534. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kadoi, K.-i. Takahashi, S. Saito, and F. Goto The comparative effects of sevoflurane versus isoflurane on cerebrovascular carbon dioxide reactivity in patients with diabetes mellitus. Anesth. Analg., July 1, 2006; 103(1): 168 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Berkowitz, R. Roberts, H. Luan, J. Peysakhov, D. L. Knoerzer, J. R. Connor, and T. C. Hohman Drug Intervention Can Correct Subnormal Retinal Oxygenation Response in Experimental Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2954 - 2960. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kadoi, S. Saito, N. Fujita, and F. Goto Risk factors for cognitive dysfunction after coronary artery bypass graft surgery in patients with type 2 diabetes J. Thorac. Cardiovasc. Surg., March 1, 2005; 129(3): 576 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kadoi, S. Saito, F. Goto, and N. Fujita The Effect of Diabetes on the Interrelationship Between Jugular Venous Oxygen Saturation Responsiveness to Phenylephrine Infusion and Cerebrovascular Carbon Dioxide Reactivity Anesth. Analg., August 1, 2004; 99(2): 325 - 331. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |